Сeftazidime/avibactam in the treatment of exacerbation of a chronic respiratory infection in patients with cystic fibrosis: dynamics of clinical, microbiological, and functional parameters

Multidrug resistance of pulmonary pathogens in patients with cystic fibrosis (CF) requires new therapeutic solutions.

The aim. To assess the effect of ceftazidime/avibactam (cef/avi) on clinical outcomes of pulmonary exacerbation of cystic fibrosis.

Methods. This open single-group observational prospective non-interventional study was conducted in the routine clinical practice settings. Patients over 18 years with a confirmed diagnosis of CF and an exacerbation of a pulmonary infection were included into the study after physician’s decision to prescribe cef/avi. The examinations were performed at baseline and on Days 5 to 7, 21, and 30.

Results. The analysis included data from 32 patients, 12 (38%) males and 20 (63%) females. The mean age was 31.6 years. Symptoms of exacerbation persisted in 97 % of patients on Days 5 to 7 of therapy and only in 3% at Day 21. FEV₁, FVC, SpO₂ also improved by Day 21 of the study (all – p < 0.001). By Day 21, proportion of patients with CRP above 10 mg/ml grew from 71 to 9%. The average density of sputum contamination decreased from 7.2 to 5.5 CFU/ml. Quality of life according to Cystic Fibrosis QuestionnaireRevised (CFQ-R) questionnaire also improved.

Conclusion. In patients with CF, exacerbation of lung infection in most cases is caused by multidrug resistant strains of Pseudomonas aeruginosa sometimes in combination with Staphylococcus aureus. Infectious agents (P. aeruginosa) remain highly sensitive to cef/avi (up to 91%) in this population so this justifies the use of cef/avi in treatment of a CF exacerbation. cef/avi administration led to relief of the exacerbation symptoms in 97% CF patients, as well as to significant improvement in spirometry parameters, increase in the oxygenation index, decrease in CRP and density of sputum contamination, and improved the quality of life. cef/avi administration was not associated with lethal outcomes, ICU admission, or serious adverse drug reactions.

1. Adeboyeku D., Jones A.L., Hodson M.E. Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis. J. Cyst. Fibros. 2011; 10 (1): 25–30. DOI: 10.1016/j.jcf.2010.09.003.

2. Mandell L.A., Wunderink R.G., Anzueto A. et al. Infectious diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 2007; 44 Suppl. 2 (Suppl. 2): S27–S72. DOI: 10.1086/511159.

3. Kondrat’eva E.I., Amelina E.L., Chernukha M.Yu. et al. [Review of clinical guidelines “Cystic fibrosis”, 2020]. Pulʹmonologiya. 2021; 31 (2): 135–147. DOI: 10.18093/0869-0189-2021-31-2-135-146 (in Russian).

4. Chebotar’ I.V., Bocharova Yu.A., Mayanskiy N.A. [Mechanisms and regulation of antimicrobial resistance in Pseudomonas aeruginosa]. Klinicheskaya microbiologiya i antimicrobnaya khimioterapiya. 2017; 19 (4): 308–319. Available at: https://cmac-journal.ru/publication/2017/4/cmac-2017-t19-n4-p308/cmac-2017-t19-n4-p308.pdf (in Russian).

5. Atkin S.D., Abid S., Foster M. et al. Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime-avibactam. Infect. Drug Resist. 2018; 11: 1499–1510. DOI: 10.2147/IDR.S173804.

6. Papp-Wallace K.M., Becka S.A., Zeiser E.T. et al. Overcoming an extremely drug resistant (XDR) pathogen: avibactam restores susceptibility to ceftazidime for Burkholderia cepacia complex isolates from cystic fibrosis patients. ACS Infect. Dis. 2017; 3 (7): 502–511. DOI: 10.1021/acsinfecdis.7b00020.

7. Stetsyuk O.U., Andreeva I.V., Lekmanov A.U., Khaikina E.V. [Ceftazidime-avibactam use in children and adolescents]. Klinicheskaya microbiologiya i antimicrobnaya khimioterapiya. 2021; 23 (2): 173–183. DOI: 10.36488/cmac.2021.2.173-183 (in Russian).

8. Spoletini G., Etherington C., Shaw N. et al. Use of ceftazidime/ avibactam for the treatment of MDR Pseudomonas aeruginosa and Burkholderia cepacia complex infections in cystic fibrosis: a case series. J. Antimicrob. Chemother. 2019; 74 (5): 1425–1429. DOI: 10.1093/jac/dky558.

9. Soriano A., Carmeli Y., Omrani A.S. et al. Ceftazidime-avibactam for the treatment of serious gram-negative infections with limited treatment options: a systematic literature review. Infect. Dis. Ther. 2021; 10 (4): 1989–2034. DOI: 10.1007/s40121-021-00507-6.

10. Sader H.S., Duncan L.R., Doyle T.B., Castanheira M. Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against Pseudomonas aeruginosa from cystic fibrosis patients. JAC Antimicrob. Resist. 2021; 3 (3): dlab126. DOI: 10.1093/jacamr/dlab126.

11. Okoliegbe I.N., Hijazi K., Cooper K. et al. Trends of antimicrobial resistance and combination susceptibility testing of multidrug-resistant pseudomonas aeruginosa isolates from cystic fibrosis patients: a 10-year update. Antimicrob. Agents Chemother. 2021; 65 (6): e02483- 20. DOI: 10.1128/AAC.02483-20.

12. Lasko M.J., Huse H.K., Nicolau D.P., Kuti J.L. Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against Pseudomonas aeruginosa from patients with cystic fibrosis. Ann. Clin. Microbiol. Antimicrob. 2021; 20 (1): 9. DOI: 10.1186/s12941-021-00415-0.

13. Ekkelenkamp M.B., Cantón R., Díez-Aguilar M. et al. Susceptibility of Pseudomonas aeruginosa recovered from cystic fibrosis patients to Murepavadin and 13 comparator antibiotics. Antimicrob Agents Chemother. 2020; 64 (2): e01541-19. DOI: 10.1128/AAC.01541-19.

14. Cantón-Bulnes M.L., Hurtado Martínez Á., López-Cerero L. et al. A case of pan-resistant Burkholderia cepacia complex bacteremic pneumonia, after lung transplantation treated with a targeted combination therapy. Transpl. Infect. Dis. 2019; 21 (2): e13034. DOI: 10.1111/tid.13034.

15. Los-Arcos I., Len O., Martín-Gómez M.T. et al. Lung transplantation in two cystic fibrosis patients infected with previously pandrug-resistant Burkholderia cepacia complex treated with ceftazidime-avibactam. Infection. 2019; 47 (2): 289–292. DOI: 10.1007/s15010-018-1261-y.

16. Tamma P.D., Fan Y., Bergman Y. et al. Successful treatment of persistent Burkholderia cepacia complex bacteremia with ceftazidime-avibactam. Antimicrob. Agents Chemother. 2018; 62 (4): e02213-17. DOI: 10.1128/AAC.02213-17.